# Bristol-Myers Squibb vs McKesson: stocks compared

URL: https://funkfolio.com/compare/bmy-vs-mck

> Bristol-Myers Squibb ($125.4B, P/E 13.6) and McKesson ($126B, P/E 28.2) compared: size, valuation, margins, debt, cash and price change.

---

## Bristol-Myers Squibb vs McKesson

Bristol-Myers Squibb (BMY), health care, and McKesson (MCK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bristol-Myers Squibb and McKesson are valued at about the same: $125.4B and $126B. Bristol-Myers Squibb trades at 13.6 times earnings and McKesson at 28.2. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and McKesson's +28.4%.

### Key facts

- **Bristol-Myers Squibb market value:** $125.4B
- **McKesson market value:** $126B
- **Bristol-Myers Squibb P/E:** 13.6
- **McKesson P/E:** 28.2
- **Bristol-Myers Squibb revenue:** $48.2B FY to 2025-12-31
- **McKesson revenue:** $403.4B FY to 2026-03-31
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 06:20 UTC.

Bristol-Myers Squibb vs McKesson: every measure side by side

| Measure | Bristol-Myers Squibb | McKesson |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size |  |  |
| Market cap | $125.4B lower | $126B higher |
| Revenue | $48.2B lower | $403.4B higher |
| Earnings | $7.1B higher | $4.8B lower |
| Employees | 32,500 lower | 41,600 higher |
| Total assets | $90B higher | $82.3B lower |
| Valuation |  |  |
| P/E | 13.6 lower | 28.2 higher |
| P/S | 2.6 higher | 0.3 lower |
| P/B | 5.4 | — |
| Dividend yield | 4.00% higher | 0.31% lower |
| Profitability |  |  |
| Operating margin | — | 1.54% |
| Balance sheet |  |  |
| Net assets | $18.5B higher | -$2.2B lower |
| Total liabilities | $71.5B lower | $83.2B higher |
| Total debt | $45.1B higher | $6.5B lower |
| Cash on hand | $10.2B higher | $4B lower |
| Price change |  |  |
| Today | -2.51% lower | -1.21% higher |
| 1 year | +33.7% higher | +28.4% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Bristol-Myers Squibb 131.1, McKesson 127.6.

- Bristol-Myers Squibb (BMY)
- McKesson (MCK)

Bristol-Myers Squibb and McKesson share prices over one year, rebased to 100: Bristol-Myers Squibb ends at 131.1, McKesson at 127.6.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | BMY | MCK |
| --- | --- | --- |
| Nov 28, 2025 | 105.1 | 103.0 |
| Dec 31, 2025 | 115.2 | 95.9 |
| Jan 30, 2026 | 117.6 | 97.2 |
| Feb 27, 2026 | 133.2 | 115.5 |
| Mar 31, 2026 | 129.6 | 101.2 |
| Apr 30, 2026 | 129.4 | 95.3 |
| May 29, 2026 | 122.2 | 86.8 |
| Jun 30, 2026 | 123.1 | 88.4 |
| Jul 31, 2026 | 139.5 | 100.1 |
| Aug 31, 2026 | 142.7 | 103.5 |
| Sep 30, 2026 | 133.3 | 99.8 |
| Oct 30, 2026 | 133.5 | 116.3 |
| Nov 17, 2026 | 131.1 | 127.6 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.6% / 0.2%

#### Bristol-Myers Squibb only (14)

- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) 2.6%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 1.6%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.1%
- [Primecap team](https://funkfolio.com/gurus/primecap) 1.0%
- [Bill Miller (founder)](https://funkfolio.com/gurus/bill-miller) 0.9%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 0.5%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.4%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) &lt;0.1%

#### McKesson only (12)

- [Ron Muhlenkamp (founder)](https://funkfolio.com/gurus/ron-muhlenkamp) 5.7%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.8%
- [Frank Sands](https://funkfolio.com/gurus/frank-sands) 0.6%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.4%
- [Stephen Mandel](https://funkfolio.com/gurus/stephen-mandel) 0.3%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.2%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%
- [Temasek](https://funkfolio.com/gurus/temasek) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / McKesson). [Who owns BMY](https://funkfolio.com/stock/BMY/superinvestors) · [Who owns MCK](https://funkfolio.com/stock/MCK/superinvestors)

### More on Bristol-Myers Squibb

- [Bristol-Myers Squibb (BMY) stock page](https://funkfolio.com/stock/BMY)
- [Bristol-Myers Squibb market cap](https://funkfolio.com/stock/BMY/market-cap)
- [Bristol-Myers Squibb revenue](https://funkfolio.com/stock/BMY/revenue)
- [Bristol-Myers Squibb P/E ratio](https://funkfolio.com/stock/BMY/pe-ratio)
- [Bristol-Myers Squibb operating margin](https://funkfolio.com/stock/BMY/operating-margin)
- [Bristol-Myers Squibb total debt](https://funkfolio.com/stock/BMY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on McKesson

- [McKesson (MCK) stock page](https://funkfolio.com/stock/MCK)
- [McKesson market cap](https://funkfolio.com/stock/MCK/market-cap)
- [McKesson revenue](https://funkfolio.com/stock/MCK/revenue)
- [McKesson P/E ratio](https://funkfolio.com/stock/MCK/pe-ratio)
- [McKesson operating margin](https://funkfolio.com/stock/MCK/operating-margin)
- [McKesson total debt](https://funkfolio.com/stock/MCK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Bristol-Myers Squibb against its closest peers

- [Bristol-Myers Squibb vs Medtronic](https://funkfolio.com/compare/bmy-vs-mdt)
- [Bristol-Myers Squibb vs Stryker](https://funkfolio.com/compare/bmy-vs-syk)
- [Bristol-Myers Squibb vs Vertex Pharmaceuticals](https://funkfolio.com/compare/bmy-vs-vrtx)

#### McKesson against its closest peers

- [McKesson vs Stryker](https://funkfolio.com/compare/mck-vs-syk)
- [McKesson vs Sanofi](https://funkfolio.com/compare/mck-vs-sny)
- [McKesson vs Medtronic](https://funkfolio.com/compare/mck-vs-mdt)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Bristol-Myers Squibb or McKesson?**

By market value, McKesson is the larger: $126B against $125.4B for Bristol-Myers Squibb. By revenue in its latest fiscal year, McKesson is the larger: $403.4B against $48.2B for Bristol-Myers Squibb.

**Which has the higher P/E ratio?**

McKesson: 28.2, against 13.6 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher dividend yield?**

Bristol-Myers Squibb: 4.00%, against 0.31% for McKesson. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Bristol-Myers Squibb: $45.1B, against $6.5B for McKesson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Bristol-Myers Squibb and McKesson?**

In their latest 13F filings, Cliff Asness holds both.

### Cite this page

Funkfolio, “Bristol-Myers Squibb vs McKesson”, data as of 18 November 2026. https://funkfolio.com/compare/bmy-vs-mck

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
